# Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

> **NCT05163106** · PHASE2 · COMPLETED · sponsor: **University Hospital, Akershus** · enrollment: 85 (actual)

## Conditions studied

- Breast Cancer
- HER2-negative Breast Cancer
- ER-positive Breast Cancer
- Locally Advanced Breast Cancer
- Luminal A Breast Cancer
- Luminal B Breast Cancer

## Interventions

- **DRUG:** Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT05163106
- **Lead sponsor:** University Hospital, Akershus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2024-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05163106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05163106, "Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05163106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*